Evidence map›Paper›PMID 30522922›Full record

Trial reportLancet (London, England)2019

Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial.

Steven Horwitz, Owen A O'Connor, Barbara Pro, Tim Illidge, Michelle Fanale, Ranjana Advani, Nancy L Bartlett, Jacob Haaber Christensen, Franck Morschhauser, Eva Domingo-Domenech and 22 more

Erratum issued Registry-linked trialOpen access · greenAbstract readClinical Trial, Phase IIIMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Lancet (London, England), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT05996185 (Phase II Study of Mogamulizumab With DA-EPOCH or CHOEP in Patients With Aggressive T-cell Lymphoma), which is not on this map. Cited by 386 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
386citing papers in PubMed, 7 pooled it
50.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05996185 phase2recruitingnot on this mapstarted 2024, after this paper: background citation

Phase II Study of Mogamulizumab With DA-EPOCH or CHOEP in Patients With Aggressive T-cell Lymphoma

TypeinterventionalSponsorYale UniversityRan2024 to 2027Enrolled22ConditionsT Cell Lymphoma, T-cell LymphomaArmsMogamulizumab, DA-EPOCH Protocol, CHOEP protocol
3 · Its place in the literature

Who cites it

386 citing papers in PubMed, 7 syntheses or guidelines pooled it, 710 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Guideline
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

326 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

32 authors at 20 institutions in 14 countries.

Steven HorwitzMemorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address: horwitzs@mskcc.org.
Owen A O'ConnorColumbia University Medical Center, New York, NY, USA.
Barbara ProDivision of Hematology and Oncology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Tim IllidgeDivision of Cancer Sciences, Faculty of Biology, Medicine and Health, University of Manchester, National Institutes of Health and Research Biomedical Research Centre, Manchester Academic Health Sciences Centre, Christie Hospital National Health Service Foundation Trust, Manchester, UK.
Michelle FanaleMD Anderson Cancer Center, University of Texas, Houston, TX, USA; Seattle Genetics, Inc, Bothell, WA, USA.
Ranjana AdvaniStanford Cancer Center, Blood and Marrow Transplant Program, Stanford, CA, USA.
Nancy L BartlettWashington University School of Medicine, St Louis, MI, USA.
Jacob Haaber ChristensenOdense University Hospital, Odense, Denmark.
Franck MorschhauserUniversity of Lille, Centre Hospitalier Universitaire de Lille, Groupe de Recherche sur les formes Injectables et les Technologies Associées, Lille, France.
Eva Domingo-DomenechInstitut Catala D'oncologia, L'Hospitalet de Llobregat, Barcelona, Spain.
Giuseppe RossiAzienda Ospedaliera Spedali Civili di Brescia, Brescia, Italy.
Won Seog KimSamsung Medical Center, Seoul, South Korea.
Tatyana FeldmanHackensack University Medical Center, Hackensack, NJ, USA.
Anne LennardFreeman Hospital, Newcastle upon Tyne, UK.
David Belada4th Department of Internal Medicine-Haematology, Charles University, Hospital and Faculty of Medicine, Hradec Králové, Czech Republic.
Árpád IllésUniversity of Debrecen, Faculty of Medicine, Department of Hematology, Debrecen, Hungary.
Kensei TobinaiNational Cancer Center Hospital, Tokyo, Japan.
Kunihiro TsukasakiSaitama Medical University International Medical Center, Saitama, Japan.
Su-Peng YehChina Medical University Hospital, Taichung, Taiwan.
Andrei ShustovUniversity of Washington Medical Center, Seattle, WA, USA.
Andreas HüttmannUniversitatsklinikum Essen, Essen, Nordrhein-Westfalen, Germany.
Kerry J SavageUniversity of British Columbia and the Department of Medical Oncology, British Columbia Cancer Centre for Lymphoid Cancer, Vancouver, BC, Canada.
Sam YuenCalvary Mater Newcastle Hospital, Waratah, NSW, Australia.
Swaminathan IyerMD Anderson Cancer Center, University of Texas, Houston, TX, USA.
Pier Luigi ZinzaniInstitute of Hematology Seràgnoli, University of Bologna, Bologna, Italy.
Zhaowei HuaMillennium Pharmaceuticals, Inc, Cambridge, MA, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company.
Meredith LittleMillennium Pharmaceuticals, Inc, Cambridge, MA, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company.
Shangbang RaoSeattle Genetics, Inc, Bothell, WA, USA.
Joseph WoolerySeattle Genetics, Inc, Bothell, WA, USA.
Thomas ManleySeattle Genetics, Inc, Bothell, WA, USA.
Lorenz TrümperUniversitätsmedizin Göttingen, Göttingen, Germany.
ECHELON-2 Study Group
Seagen (United States) · USCharles University · CZInstitut Català d'Oncologia · ESMemorial Sloan Kettering Cancer Center · USStanford Blood Center · USThe University of Texas MD Anderson Cancer Center · USUniversity of Bologna · ITUniversity of Washington Medical Center · USAzienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia · ITCalvary Mater Newcastle Hospital · AUColumbia University Irving Medical Center · USEssen University Hospital · DEFreeman Hospital · GBHackensack University Medical Center · USNational Health Service · GBNorthwestern University · USOdense University Hospital · DKSaitama International Medical Center · JPSamsung Medical Center · KRTakeda (United States) · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
NCI NIH HHS P30 CA008748NCI NIH HHS P30 CA016672
6 · The paper itself

Abstract

backgroundBased on the encouraging activity and manageable safety profile observed in a phase 1 study, the ECHELON-2 trial was initiated to compare the efficacy and safety of brentuximab vedotin, cyclophosphamide, doxorubicin, and prednisone (A+CHP) versus cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) for the treatment of CD30-positive peripheral T-cell lymphomas.

methodsECHELON-2 is a double-blind, double-dummy, randomised, placebo-controlled, active-comparator phase 3 study. Eligible adults from 132 sites in 17 countries with previously untreated CD30-positive peripheral T-cell lymphomas (targeting 75% with systemic anaplastic large cell lymphoma) were randomly assigned 1:1 to receive either A+CHP or CHOP for six or eight 21-day cycles. Randomisation was stratified by histological subtype according to local pathology assessment and by international prognostic index score. All patients received cyclophosphamide 750 mg/m

findingsBetween Jan 24, 2013, and Nov 7, 2016, 601 patients assessed for eligibility, of whom 452 patients were enrolled and 226 were randomly assigned to both the A+CHP group and the CHOP group. Median progression-free survival was 48·2 months (95% CI 35·2-not evaluable) in the A+CHP group and 20·8 months (12·7-47·6) in the CHOP group (hazard ratio 0·71 [95% CI 0·54-0·93], p=0·0110). Adverse events, including incidence and severity of febrile neutropenia (41 [18%] patients in the A+CHP group and 33 [15%] in the CHOP group) and peripheral neuropathy (117 [52%] in the A+CHP group and 124 [55%] in the CHOP group), were similar between groups. Fatal adverse events occurred in seven (3%) patients in the A+CHP group and nine (4%) in the CHOP group.

interpretationFront-line treatment with A+CHP is superior to CHOP for patients with CD30-positive peripheral T-cell lymphomas as shown by a significant improvement in progression-free survival and overall survival with a manageable safety profile.

fundingSeattle Genetics Inc, Millennium Pharmaceuticals Inc, a wholly owned subsidiary of Takeda Pharmacuetical Company Limited, and National Institutes of Health National Cancer Institute Cancer Center.

Indexed as

AdultAgedAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsBrentuximab VedotinCyclophosphamideDisease-Free SurvivalDouble-Blind MethodDoxorubicinFemaleHumansImmunoconjugatesImmunologic FactorsIntention to Treat AnalysisLymphoma, Large-Cell, AnaplasticMaleAntineoplastic AgentsBrentuximab VedotinCyclophosphamideDoxorubicinImmunoconjugatesImmunologic FactorsPrednisoneVincristine

Identifiers

PMID30522922
PMCPMC6436818
OpenAlexW2903308035

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.